Investing.comDoubao · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 19:04:31·⟳ 抓取 19:04:58 +27s·⚡ 决策 10-16 19:06:52 +1m54s·11.1 天前
Tango Therapeutics 预告将在 ESMO 2026 公布 vopimetostat 胰腺癌/肺癌 I/II 期更新数据，但当前仅为日程预告、无任何疗效数据
这是一条典型的'将在学术会议展示数据'的会前日程预告（且原文标注 AI 生成），没有任何疗效、安全性或注册进展的新增事实；真正的催化在 10-19 摘要上线与 10-23/25 数据公布。临床期 biotech 在数据空白下做多或做空都缺乏基本面 edge，且距首个数据锚点还有 3 天，当前入场等于裸赌二元数据结果，故 AVOID；待摘要/数据发布后按实际读数另行研判。
📄 原文Investing.com↗ 原文
Tango Therapeutics to present pancreatic cancer study data
BOSTON - Tango Therapeutics, Inc. (NASDAQ:TNGX) will present updated data from a Phase 1/2 study of vopimetostat combin…
不做 Tango Therapeutics（TNGX.US）
本条仅为 ESMO 数据展示的日程预告，无任何疗效/安全性/注册增量，属中性事件；真正二元催化在 10-19 摘要上线与 10-23/25 数据公布，距首个锚点尚有 3 天，无数据下多空均无 edge，不提前裸赌，待摘要或正式数据发布后再按实际读数研判。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
TNGX 仅预告 ESMO 壁报与 webcast 时间，未披露任何数据，属中性日程提醒而非疗效催化；在临床期公司二元数据事件前、且距摘要发布尚有 3 天，无方向 edge，不做。
🔎 新鲜度:最早出现 2026-10-16 · 扩散 low · price-in 风险 low ↗
主要风险
- 10-19 摘要可能含初步疗效数字并引发盘前跳空，届时方向与价格一次性重定价，当前持仓无法据空白信息管理该二元风险
- 若数据超预期或不及预期，临床期小盘 biotech 波动极大，提前埋伏的胜率与赔率均无法在无数据下评估
反向证据
- 做多前查反向 · 来源 web · 影响 weakens
正文仅为会前预告、未含读数；在数据未公开前无正向证据，也无依据把预告本身当利好。
检索:Tango Therapeutics vopimetostat ESMO 2026 pancreatic data already released / partial clinical hold / safety 原文 ↗
先例如何影响了这次决策
对本次决策的影响:未据此给任何仓位或 tp/sl；结论为等数据落地后再就真实催化做先例研究与交易。
方向:无可对照先例；且本事件为无数据的会议日程预告，价格反应由未来真实数据决定，历史'纯预告'先例不具可迁移方向意义。
涨幅量级:无 aligned 先例可校准幅度；临床期 biotech 的实际涨跌应锚定 10-19 摘要与 10-23/25 数据发布事件，而非本条预告。
形态:不足以判断见光死或方向
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 29 ms
{"result": "search_processed_events:agent query=`tango therapeutics abstract 3149p esmo presentation october 2026 | tango therapeutics tngx esmo 2026 vopimetostat daraxonrasib zoldonrasib pancreatic`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是
原文全文
展开原文 · 1,425 字
BOSTON - Tango Therapeutics, Inc. (NASDAQ:TNGX) will present updated data from a Phase 1/2 study of vopimetostat combined with daraxonrasib or zoldonrasib in patients with MTAP deleted RAS mutant metastatic pancreatic ductal adenocarcinoma and non-small cell lung cancer at the European Society For Medical Oncology Congress 2026, according to a press release statement.
The congress will be held October 23-27, 2026 in Madrid, Spain. Abstracts will be available on the ESMO website on Monday, October 19, 2026 at 12:05 am CEST.
The poster presentation will include updated data beyond the April 3, 2026 data cutoff date referenced in the abstract. Dr. Alexander I. Spira from NEXT Oncology in Fairfax will present the findings on Sunday, October 25, 2026 from 12:00 to 12:45 pm CEST. The abstract number is 3149P.
The company will host a webcast focused on the pancreatic ductal adenocarcinoma data on Friday, October 23, 2026 at 7:30 am ET. The webcast will be accessible in the Investors section of the company’s website and will remain available for replay for at least 30 days.
Tango Therapeutics is a clinical-stage biotechnology company focused on developing precision cancer medicines using synthetic lethality principles to identify drug targets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Tango Therapeutics to present pancreatic cancer study data
The congress will be held October 23-27, 2026 in Madrid, Spain. Abstracts will be available on the ESMO website on Monday, October 19, 2026 at 12:05 am CEST.
The poster presentation will include updated data beyond the April 3, 2026 data cutoff date referenced in the abstract. Dr. Alexander I. Spira from NEXT Oncology in Fairfax will present the findings on Sunday, October 25, 2026 from 12:00 to 12:45 pm CEST. The abstract number is 3149P.
The company will host a webcast focused on the pancreatic ductal adenocarcinoma data on Friday, October 23, 2026 at 7:30 am ET. The webcast will be accessible in the Investors section of the company’s website and will remain available for replay for at least 30 days.
Tango Therapeutics is a clinical-stage biotechnology company focused on developing precision cancer medicines using synthetic lethality principles to identify drug targets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Tango Therapeutics to present pancreatic cancer study data
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
ae94a862ff· 2026-10-16 19:06 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前